

A.D.A.M. Innovations, SOPHiA GENETICS to advance liquid biopsy testing in Japan

October 17, 2025 | News

The companies aim to develop a liquid biopsy companion diagnostic (CDx) test in Japan



A.D.A.M. Innovations, Japan's leading private genetic testing company, and Swiss-based SOPHiA GENETICS, have announced a strategic agreement to bring cutting-edge liquid biopsy genomic testing to the Japanese population. The companies will also partner to commercialize a liquid biopsy companion diagnostic aimed at advancing personalized and precision cancer care in Japan.

As a market leader for genetic testing in Japan with a high-throughput laboratory located in central Tokyo, A.D.A.M. Innovations has served the Japanese population for over 20 years and completed over 2.8 million genomic tests to-date. A.D.A.M. Innovations will continue its legacy of bringing global innovations to Japan by adopting the AI-powered SOPHiA DDM™ Platform to advance personalized cancer testing across the country.

The partnership will initially focus on launching the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDM™. This innovative liquid biopsy test is designed to detect actionable genomic alterations from a single blood draw, leveraging state-of-the-art AI to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner. The test utilizes a matched tumor-normal approach which improves accuracy and avoids false positives. By launching the test locally and analyzing samples in-house, A.D.A.M. Innovations will expedite testing turnaround times, reduce costs to patients, and advance local cancer research.

As part of the partnership, the companies also aim to develop a liquid biopsy companion diagnostic (CDx) test in Japan. By developing the application into a CDx, more patients can gain access to the benefits of the high-quality tumor profiling test, advancing personalized healthcare at scale. The offering will also provide pharmaceutical partners with a powerful new tool to accelerate drug development and market access in Japan. The companies will collaborate across all steps of the development process, with A.D.A.M. Innovations leveraging its deep clinical and regulatory expertise to support regulatory submissions in Japan.